Ulcerative ColitisNCT02729233
Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction
A study testing patients receiving biopsies in people with Ulcerative Colitis, run by University of Arkansas.
Trial summary
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD). UC is an ongoing disease of the colon or large intestine. Studies have shown that leakiness of the gut plays a major role in the development of UC. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Ulcerative Colitis
- What is being tested?
- patients receiving biopsies
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Jan 2017to 27 Jan 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of ulcerative colitis based on standard clinical, radiological, endoscopic and histological criteria with moderate-to-severe disease activity, defined as a Mayo score of 6-12, with an endoscopic subscore of 2 or more.
- Age 18-75 years
- Patients about to be started on golimumab therapy because of moderate to severe flare, steroid dependence, or failure of other therapies.
- Inadequate response to or failure to tolerate 1 or more of the following conventional therapies:
- Oral 5-aminosalicylates (5-ASAs)
- Oral corticosteroids
Show all 17Show fewer
- Immunosuppressives (azathioprine (AZA) or 6-mercaptopurine) OR
- Corticosteroid-dependent (i. e., could not taper corticosteroids without recurrence of UC symptoms) AND
- No previous exposure to biological therapy (TNF naïve)
- Patients concurrently treated with oral 5-aminosalicylates or corticosteroids must have maintained stable dose for ≥ 2 weeks before baseline.
- Patients concurrently treated with AZA and/or 6-mercaptopurine must have maintained stable dose for ≥ 4 weeks before baseline.
- Tuberculosis (TB) related screening criteria:
- No history of latent or active tuberculosis (TB) prior to screening. An exception is made for subjects who have a history of latent TB and are currently receiving treatment for latent TB, will initiate treatment for latent TB prior to first administration of golimumab, or have documentation of having completed appropriate treatment for latent TB within 3 years prior to the first administration of golimumab.
- No signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- No recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to the first administration of study agent.
- Within 2 months prior to the first administration of golimumab, have a negative QuantiFERON®-TB Gold test result, or have a newly identified positive QuantiFERON®-TB Gold test result in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated prior to the first administration of study agent. Subjects with persistently indeterminate QuantiFERON®-TB Gold test results may be enrolled without treatment for latent TB, if active TB is ruled out, their chest radiograph shows no abnormality suggestive of TB (active or old, inactive TB), and the subject has no additional risk factors for TB as determined by the principal investigator.
- Have a chest radiograph posterior-anterior views, taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current, active TB or old, inactive TB.
Who cannot join
- Pregnancy/nursing.
- Known allergies to IV contrast or shellfish.
- Impaired renal function (serum creatinine over 1.5 mg/dL).
- Uncontrolled or severe asthma.
- Active infection.
- Active or previously identified latent tuberculosis.
Show all 32Show fewer
- History of systemic lupus.
- Current or history of demyelinating neurological disease.
- Current or history of congestive heart failure.
- History of or at imminent risk for colectomy.
- Gastrointestinal surgery ≤ 2 months prior to screening for study entry.
- Colitis limited to 20 cm. of the colon.
- History of colonic mucosal dysplasia or adenomatous colonic polyps that were not removed.
- Screening stool sample positive for enteric pathogens or Clostridium difficile toxin.
- Previous use of the following medications:
- Biologic anti-TNF agent(s) natalizumab or other agents targeting the α-4integrin, B-cell-depleting agents (rituximab) or T-cell-depleting agents (vedolizumab, visilizumab) within 12 months of study entry.
- Continued B- or T-cell depletion ˃ 12 months after completing therapy with lymphocyte-depleting agents.
- Oral corticosteroids at a dose ˃ 40 mg. prednisone or its equivalent per day
- Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of study entry.
- Use of an investigational agent within 5 half-lives of that agent prior to study entry.
- History of any malignancy.
- History of active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening.
- Subjects must undergo screening for hepatitis B virus (HBV). At a minimum, this includes testing for HBsAg (HBV surface antigen), anti-HBs (HBV surface antibody), and anti-HBc total (HBV core antibody total):
- Subjects who test negative for all HBV screening tests (ie, HBsAg-, anti-HBc-, and anti HBs-) are eligible for this study.
- Subjects who test positive for surface antigen (HBsAg+) are not eligible for this study, regardless of the results of other hepatitis B tests.
- Subjects who test negative for surface antigen (HBsAg-) and test positive for core antibody (anti-HBc+) and surface antibody (anti-HBs+) are eligible for this study.
- Subjects who test positive only for surface antibody (anti-HBs+) are eligible for this study.
- Subjects who test positive only for core antibody (anti-HBc+) must undergo further testing for hepatitis B deoxyribonucleic acid (HBV DNA test). If the HBV DNA test is positive, the subject is not eligible for this study. If the HBV DNA test is negative, the subject is eligible for this study. In the event the HBV DNA test cannot be performed, the subject is not eligible for this study.
- 1. Subjects with a positive HBV DNA test will be counselled per the clinical Hepatitis B Positive Screen Standard Operating Procedure (SOP). If the HBV DNA test cannot be performed, the subject will be counselled per the SOP at the physician's discretion.
- 19. Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening.
- 20. Have a chest radiograph within 3 months prior to the first administration of golimumab that shows an abnormality suggestive of a malignancy or current active infection, including TB.
- 21. Have had a nontuberculous mycobacterial infection or opportunistic infection (e. g., cytomegalovirus, pneumocystosis, aspergillosis) within 6 months prior to screening.
About this study
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD). UC is an ongoing disease of the colon or large intestine. Studies have shown that leakiness of the gut plays a major role in the development of UC. Leakiness of the gut is a condition that is a result of damage to the intestinal lining, making it less able to protect its internal environment as well as to filter needed nutrients and other substances. Some bacteria, toxins, and waste not normally absorbed may get into the blood stream.
Golimumab is an FDA approved medication used for the treatment of moderate to severe ulcerative colitis. The investigators have evidence to suggest that measuring the leakiness of the gut using a tool called a confocal laser endomicroscope may be able to predict how well a patient's body will respond to treatment of UC with golimumab. Confocal laser endomicroscopy (CLE) is an FDA approved technique that can look at the cells of a patient's gut during colonoscopy to assess the leakiness of gut.
The objective of this study is to determine how the leakiness of the gut in patients with UC can predict response to golimumab therapy.
Read the detailed description
The objective of this pilot study is to determine the predictive value of mucosal barrier dysfunction for a therapeutic response to golimumab in UC patients. This objective is based on the investigator's hypothesis that barrier dysfunction is a potent predictor of response to anti-tumor necrosis factor (TNF) therapy. This hypothesis is based on the following observations: (1) IBD patients with higher gap densities have higher mucosal pro-inflammatory cytokine levels; (2) the highest rates of response to biologic therapy for Ulcerative colitis are seen in post-operative patients, with over 90% endoscopic remission rate at one year; and (3) prominent barrier dysfunction is observed at the anastomotic site in animal models of ileal resection. Therefore, the investigators hypothesize that barrier dysfunction is a potent predictor of therapeutic response to golimumab in UC patients.
In 30 UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based CLE (pCLE). Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
Secondary study endpoints are: (1) The rate of clinical remission at 3 months following initiation of golimumab. (2) The rate of clinical remission at 12 months following initiation of golimumab. (3) Endoscopic and histological evidence of mucosal healing at one-year follow-up colonoscopy.
Clinical Response \& Remission definitions are: (1) Clinical Remission: partial Mayo score of 2 points, without any sub-score >1. (2) Clinical Response: reduction of partial Mayo UC score by ≥ 30% and ≥ 2 points, with a rectal bleeding sub-score of ≤ 1 or a decrease in the bleeding sub-score of ≥ 1.
Endoscopic and histologic mucosal healing definitions: (1) Endoscopic: Mayo endoscopic score of 0 or 1. (2) Histologic: Riley's histological score ≤ 6.
The investigators proposal is based on clinical, translational and basic evidence of barrier dysfunction in the pathogenesis of UC. With the development of a robust prediction model for therapeutic response, UC patients can be treated more effectively with golimumab. Using a stratified approach, higher therapeutic response rate may eventually yield a new "intelligent step-up" treatment strategy in this personalized medicine era.
- Conditions
- Ulcerative Colitis
- Being tested
- patients receiving biopsies
- Keywords
- mucosal barrier function
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
patients receiving biopsiesOther
Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
| Study group | Role | What they receive |
|---|---|---|
| patients receiving biopsies | Other | UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE). Receives: Other: patients receiving biopsies |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of improvement in mucosal barrier function as measured by pCLE
Measured: up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2016 (estimated)
- Study startJan 2017
- Primary completion27 Jan 2017
- Study completion27 Jan 2017
Why it stopped: Funding withdrawn
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative ColitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Arkansas
- Sponsor type
- University, hospital or other
- Collaborators
- Janssen Scientific Affairs, LLC
- Responsible party
- Sponsor
- Investigators
- Julia J Liu, MD, Principal investigator, University of Arkansas
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02729233
- Sponsor's protocol ID
- 205241
- Status last verified
- Jan 2018
- First submitted
- 31 Mar 2016
- Last updated
- 8 Jan 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction
- ClinicalTrials.gov ID
- NCT02729233
- Acronym / sponsor ID
- 205241
- Conditions
- Ulcerative Colitis
- Keywords
- mucosal barrier function
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Funding withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of ArkansasUniversity, hospital or other
- Collaborators
- Janssen Scientific Affairs, LLC
- Study start
- Jan 2017
- Primary completion
- 27 Jan 2017 (actual)
- Study completion
- 27 Jan 2017 (actual)
- First posted
- 6 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD). UC is an ongoing disease of the colon or large intestine. Studies have shown that leakiness of the gut plays a major role in the development of UC. Leakiness of the gut is a condition that is a result of damage to the intestinal lining, making it less able to protect its internal environment as well as to filter needed nutrients and other substances. Some bacteria, toxins, and waste not normally absorbed may get into the blood stream.
Golimumab is an FDA approved medication used for the treatment of moderate to severe ulcerative colitis. The investigators have evidence to suggest that measuring the leakiness of the gut using a tool called a confocal laser endomicroscope may be able to predict how well a patient's body will respond to treatment of UC with golimumab. Confocal laser endomicroscopy (CLE) is an FDA approved technique that can look at the cells of a patient's gut during colonoscopy to assess the leakiness of gut.
The objective of this study is to determine how the leakiness of the gut in patients with UC can predict response to golimumab therapy.
Detailed description
The objective of this pilot study is to determine the predictive value of mucosal barrier dysfunction for a therapeutic response to golimumab in UC patients. This objective is based on the investigator's hypothesis that barrier dysfunction is a potent predictor of response to anti-tumor necrosis factor (TNF) therapy. This hypothesis is based on the following observations: (1) IBD patients with higher gap densities have higher mucosal pro-inflammatory cytokine levels; (2) the highest rates of response to biologic therapy for Ulcerative colitis are seen in post-operative patients, with over 90% endoscopic remission rate at one year; and (3) prominent barrier dysfunction is observed at the anastomotic site in animal models of ileal resection. Therefore, the investigators hypothesize that barrier dysfunction is a potent predictor of therapeutic response to golimumab in UC patients.
In 30 UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based CLE (pCLE). Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
Secondary study endpoints are: (1) The rate of clinical remission at 3 months following initiation of golimumab. (2) The rate of clinical remission at 12 months following initiation of golimumab. (3) Endoscopic and histological evidence of mucosal healing at one-year follow-up colonoscopy.
Clinical Response \& Remission definitions are: (1) Clinical Remission: partial Mayo score of 2 points, without any sub-score >1. (2) Clinical Response: reduction of partial Mayo UC score by ≥ 30% and ≥ 2 points, with a rectal bleeding sub-score of ≤ 1 or a decrease in the bleeding sub-score of ≥ 1.
Endoscopic and histologic mucosal healing definitions: (1) Endoscopic: Mayo endoscopic score of 0 or 1. (2) Histologic: Riley's histological score ≤ 6.
The investigators proposal is based on clinical, translational and basic evidence of barrier dysfunction in the pathogenesis of UC. With the development of a robust prediction model for therapeutic response, UC patients can be treated more effectively with golimumab. Using a stratified approach, higher therapeutic response rate may eventually yield a new "intelligent step-up" treatment strategy in this personalized medicine era.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients receiving biopsies | Other | Other: patients receiving biopsiesUC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE). |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Diagnosis of ulcerative colitis based on standard clinical, radiological, endoscopic and histological criteria with moderate-to-severe disease activity, defined as a Mayo score of 6-12, with an endoscopic subscore of 2 or more.
- Age 18-75 years
- Patients about to be started on golimumab therapy because of moderate to severe flare, steroid dependence, or failure of other therapies.
- Inadequate response to or failure to tolerate 1 or more of the following conventional therapies:
- Patients concurrently treated with oral 5-aminosalicylates or corticosteroids must have maintained stable dose for ≥ 2 weeks before baseline.
Key exclusion criteria (32 listed)
- Pregnancy/nursing.
- Known allergies to IV contrast or shellfish.
- Impaired renal function (serum creatinine over 1.5 mg/dL).
- Uncontrolled or severe asthma.
- Active infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| patients receiving biopsiesSix mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab. | Other | patients receiving biopsies |
Primary outcome
Rate of improvement in mucosal barrier function as measured by pCLE
Time frame: up to 12 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2018.
- Individual participant dataSharing planned: No
Related trials for Ulcerative Colitis
RecruitingPhase 2
A Study of AC-101 Tablets in Patients With Ulcerative Colitis
Ulcerative Colitis (UC)
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
Not yet recruitingPhase 1
Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
RecruitingPhase 4
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ulcerative Colitis, Crohn's Disease
Recruiting
Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel Disease
Crohn Disease and Ulcerative Colitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julia J Liu, MD principal investigator
University of Arkansas
Questions about this trial
What is this clinical trial studying?
A study testing patients receiving biopsies in people with Ulcerative Colitis, run by University of Arkansas.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 8 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of improvement in mucosal barrier function as measured by pCLE (time frame: up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2018.